#asco26
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26
Mark Lewis, MD, FASCO1,169,633 Aufrufe • vor 1 Monat
This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 Toni Choueiri, MD Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) Dr. Cathy Eng Sumanta K. Pal, MD, FASCO Tom Powles Brian Rini, MD Daniel Castellano gilberto lopes Petros Grivas Dra. María Natalia Gandur Quiroga Emre Yekedüz Neeraj Agarwal, MD, FASCO ASCO ONCOassist® | The go-to oncology app Open Medicine Kate Sears Simon C 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 UroToday.com OncLive.com Cristiane D Bergerot, PhD, FASCO International Urology Cancer Summit Dr Amol Akhade LARVOL IMG Oncologists
Yüksel Ürün195,828 Aufrufe • vor 1 Monat
Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations ASCO #ASCO26 OncoAlert
Jame Abraham, MD, FACP105,168 Aufrufe • vor 1 Monat
A historic moment at #ASCO26: more than 9,000 oncologists rose for three standing ovations as Brian Wolpin, MD, MPH, Director of the Hale Family Center for Pancreatic Cancer Research, presented promising new Phase 3 results for an investigational treatment for metastatic pancreatic cancer. In the trial, daraxonrasib helped patients with previously treated metastatic pancreatic cancer live significantly longer than those who received chemotherapy. While more work remains, these findings offer something powerful: hope for patients and families facing one of the most challenging cancers. As Dr. Wolpin said, “It is exciting to see that we may soon be able to help patients with metastatic pancreatic cancer in ways we haven’t been able to before, improving both survival and quality of life.” Congratulations to the researchers and patients who made this important progress possible. 👏👏👏 Video Courtesy: ASCO
Dana-Farber52,509 Aufrufe • vor 1 Monat
Lung Cancer Conference Highlights from #ASCO26 w/ Isabel Preeshagul ✅ #LIBRETTO432 ✅ #CROWN (& LORIN) ✅ #CHRYSALIS2 ✅ #HARMONi6 ✅ A quick mention about DeLLphi304 Full 🗣️ ⭐️ OncBrothers & OncUpdates website ⭐️“Oncology Brothers” podcast #OncTwitter #lcsm #MedTwitter
Oncology Brothers15,115 Aufrufe • vor 1 Monat
Witnessed the arrival of a potential game changer👀 #ASCO26 Plenary Session 🔥 RASolute 302 in RAS G12D–mutant pancreatic cancer Daraxonrasib showed a striking OS benefit vs chemotherapy: ✅ mOS 13.2 vs 6.6 months, HR 0.40 ✅ 12-mo OS 53.3% vs 18.7%
Masahiro TORASAWA, MD. PhD.12,773 Aufrufe • vor 1 Monat
